{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:18:32Z","timestamp":1789582712277,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:00:00Z","timestamp":1662508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:00:00Z","timestamp":1662508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"zambon"},{"DOI":"10.13039\/501100007642","name":"Universit\u00e0 degli Studi di Roma Tor Vergata","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007642","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Parkinson\u2019s disease (PD) is characterized by motor symptoms often experienced in concomitance with non-motor symptoms (NMS), such as depression, apathy, pain, sleep disorders, and urinary dysfunction. The present study aimed to explore the effect of safinamide treatment on NMS and quality of life in motor-fluctuating PD patients. VALE-SAFI is an observational single-centre study performed\u00a0in fluctuating PD patients starting safinamide treatment\u00a0and followed for 6 months. The effects of safinamide on NMS, sleep, fatigue, depression and pain were assessed through validated sales. Changes in the scales from baseline to the\u00a06-month follow-up visit\u00a0were analysed. 60 PD patients (66.67% males) were enrolled at baseline, and 45 patients completed the 6-month follow-up. PD patients improved motor symptoms at follow-up, with the significant reduction of motor fluctuations. The global score of the NMS Scale significantly decreased between baseline and the follow-up. Regarding pain domains, patients reported a significant improvement in discolouration and oedema\/swelling. Further, a significant improvement was observed from baseline to follow-up in sleep quality measured through the Pittsburgh Sleep Quality Index, while no changes were documented in daytime sleepiness. No differences were found in depression and fatigue between baseline and follow-up. Finally, the patient\u2019s perception of the impact of PD on functioning and well-being decreased from baseline to follow-up. The present findings confirmed the beneficial effect of safinamide on both motor and non-motor symptoms, also improving the quality of life of PD patients. Furthermore, these data support the positive effects of safinamide on pain and mood, as well as on sleep quality and continuity.\n<\/jats:p>","DOI":"10.1007\/s00702-022-02538-w","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T07:04:07Z","timestamp":1662534247000},"page":"1331-1338","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Non-motor symptoms burden in motor-fluctuating patients with Parkinson\u2019s disease may be alleviated by safinamide: the VALE-SAFI study"],"prefix":"10.1007","volume":"129","author":[{"given":"Claudia","family":"De Masi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Liguori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Spanetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Cerroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Garasto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Pierantozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola Biagio","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Stefani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,7]]},"reference":[{"key":"2538_CR1","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1007\/s00415-012-6557-8","volume":"259","author":"A Antonini","year":"2012","unstructured":"Antonini A, Barone P, Marconi R et al (2012) The progression of non-motor symptoms in Parkinson\u2019s disease and their contribution to motor disability and quality of life. J Neurol 259:2621\u20132631. https:\/\/doi.org\/10.1007\/s00415-012-6557-8","journal-title":"J Neurol"},{"key":"2538_CR2","doi-asserted-by":"crossref","unstructured":"Beck AT, Steer RA, Brown G (1996) Beck depression inventory\u2013II. Psychol Assess","DOI":"10.1037\/t00742-000"},{"key":"2538_CR3","doi-asserted-by":"publisher","unstructured":"Bianchi MLE, Riboldazzi G, Mauri M, Versino M (2019) Correction to: Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson\u2019s disease (Neurological Sciences, (2019), 40, 2, (275\u2013279), https:\/\/doi.org\/10.1007\/s10072-018-3628-3). Neurol Sci 40:281. https:\/\/doi.org\/10.1007\/s10072-018-3658-x","DOI":"10.1007\/s10072-018-3628-3 10.1007\/s10072-018-3658-x"},{"key":"2538_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.parkreldis.2004.07.007","volume":"11","author":"RG Brown","year":"2005","unstructured":"Brown RG, Dittner A, Findley L, Wessely SC (2005) The Parkinson fatigue scale. Park Relat Disord 11:49\u201355. https:\/\/doi.org\/10.1016\/j.parkreldis.2004.07.007","journal-title":"Park Relat Disord"},{"key":"2538_CR5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","volume":"28","author":"DJ Buysse","year":"1989","unstructured":"Buysse DJ, Reynolds CF III, Monk TH et al (1989) The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28:193\u2013213","journal-title":"Psychiatry Res"},{"key":"2538_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3233\/JPD-191765","volume":"10","author":"C Cattaneo","year":"2020","unstructured":"Cattaneo C, Jost WH, Bonizzoni E (2020) Long-term efficacy of safinamide on symptoms severity and quality of life in fluctuating Parkinson\u2019s Disease patients. J Parkinsons Dis 10:89\u201397. https:\/\/doi.org\/10.3233\/JPD-191765","journal-title":"J Parkinsons Dis"},{"key":"2538_CR7","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2165\/00002018-200225070-00001","volume":"25","author":"KR Chaudhuri","year":"2002","unstructured":"Chaudhuri KR, Pal S, Brefel-Courbon C (2002) \u201cSleep attacks\u201d or \u201cunintended sleep episodes\u201d occur with dopamine agonists: Is this a class effect? Drug Saf 25:473\u2013483. https:\/\/doi.org\/10.2165\/00002018-200225070-00001","journal-title":"Drug Saf"},{"key":"2538_CR8","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1002\/mds.21596","volume":"22","author":"KR Chaudhuri","year":"2007","unstructured":"Chaudhuri KR, Martinez-Martin P, Brown RG et al (2007) The metric properties of a novel non-motor symptoms scale for Parkinson\u2019s disease: results from an international pilot study. Mov Disord 22:1901\u20131911","journal-title":"Mov Disord"},{"key":"2538_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/biom11040612","author":"FC Church","year":"2021","unstructured":"Church FC (2021) Review treatment options for motor and non-motor symptoms of parkinson\u2019s disease. Biomolecules. https:\/\/doi.org\/10.3390\/biom11040612","journal-title":"Biomolecules"},{"key":"2538_CR10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.parkreldis.2016.10.020","volume":"34","author":"I Cova","year":"2017","unstructured":"Cova I, Di Battista ME, Vanacore N et al (2017) Validation of the Italian version of the non motor symptoms scale for Parkinson\u2019s disease. Parkinsonism Relat Disord 34:38\u201342","journal-title":"Parkinsonism Relat Disord"},{"key":"2538_CR11","doi-asserted-by":"publisher","unstructured":"Curcio G, Tempesta D, Scarlata S, et al (2013) Validity of the Italian Version of the Pittsburgh Sleep Quality Index (PSQI) 511\u2013519. https:\/\/doi.org\/10.1007\/s10072-012-1085-y","DOI":"10.1007\/s10072-012-1085-y"},{"key":"2538_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-021-05324-w","author":"R De Micco","year":"2021","unstructured":"De Micco R, Satolli S, Siciliano M et al (2021) Effects of safinamide on non-motor, cognitive, and behavioral symptoms in fluctuating Parkinson\u2019s disease patients: a prospective longitudinal study. Neurol Sci. https:\/\/doi.org\/10.1007\/s10072-021-05324-w","journal-title":"Neurol Sci"},{"key":"2538_CR13","unstructured":"Fahn S, Elton R (1987) Unified Parkinson\u2019s Disease Rating Scale. In: Fahn S, Marsden C, Calne D, Goldstein M (eds) Recent developments in Parkinson\u2019s disease. MacMillan Healthcare Information, Florham Park, pp 153\u2013164"},{"key":"2538_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.678373","author":"M Fernandes","year":"2021","unstructured":"Fernandes M, Pierantozzi M, Stefani A et al (2021) Frequency of non-motor symptoms in Parkinson\u2019s Patients with motor fluctuations. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2021.678373","journal-title":"Front Neurol"},{"key":"2538_CR15","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1007\/s10072-018-3524-x","volume":"39","author":"G Galeoto","year":"2018","unstructured":"Galeoto G, Colalelli F, Massai P et al (2018) Quality of life in Parkinson\u2019s disease: Italian validation of the Parkinson\u2019s Disease Questionnaire (PDQ-39-IT). Neurol Sci 39:1903\u20131909","journal-title":"Neurol Sci"},{"key":"2538_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/JPM11080798","author":"DS Garc\u00eda","year":"2021","unstructured":"Garc\u00eda DS, Ba\u00f1a RY, Guerra CL et al (2021a) Pain improvement in parkinson\u2019s disease patients treated with safinamide: results from the safinonmotor study. J Pers Med. https:\/\/doi.org\/10.3390\/JPM11080798","journal-title":"J Pers Med"},{"key":"2538_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/brainsci11030316","volume":"11","author":"DS Garc\u00eda","year":"2021","unstructured":"Garc\u00eda DS, Guerra CL, Ba\u00f1a RY et al (2021b) Safinamide improves non-motor symptoms burden in parkinson\u2019s disease: an open-label prospective study. Brain Sci 11:1\u201315. https:\/\/doi.org\/10.3390\/brainsci11030316","journal-title":"Brain Sci"},{"key":"2538_CR18","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s00702-020-02218-7","volume":"127","author":"C Geroin","year":"2020","unstructured":"Geroin C, Di Vico IA, Squintani G et al (2020) Effects of safinamide on pain in Parkinson\u2019s disease with motor fluctuations: an exploratory study. J Neural Transm 127:1143\u20131152. https:\/\/doi.org\/10.1007\/s00702-020-02218-7","journal-title":"J Neural Transm"},{"key":"2538_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/brb3.2336","volume":"11","author":"S Grigoriou","year":"2021","unstructured":"Grigoriou S, Mart\u00ednez-Mart\u00edn P, Ray Chaudhuri K et al (2021) Effects of safinamide on pain in patients with fluctuating Parkinson\u2019s disease. Brain Behav 11:1\u20139. https:\/\/doi.org\/10.1002\/brb3.2336","journal-title":"Brain Behav"},{"key":"2538_CR20","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/1531-8257(200007)15:4<658::AID-MDS1009>3.0.CO;2-N","volume":"15","author":"RA Hauser","year":"2000","unstructured":"Hauser RA, Gauger L, Anderson WMD, Zesiewicz TA (2000) Pramipexole-induced somnolence and episodes of daytime sleep. Mov Disord 15:658\u2013663. https:\/\/doi.org\/10.1002\/1531-8257(200007)15:4%3c658::AID-MDS1009%3e3.0.CO;2-N","journal-title":"Mov Disord"},{"key":"2538_CR21","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/ageing\/26.5.353","volume":"26","author":"C Jenkinson","year":"1997","unstructured":"Jenkinson C, Fitzpatrick RAY, Peto VIV et al (1997) The Parkinson\u2019s Disease Questionnaire (PDQ-39): development and validation of a Parkinson\u2019s disease summary index score. Age Ageing 26:353\u2013357","journal-title":"Age Ageing"},{"key":"2538_CR22","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","volume":"14","author":"MW Johns","year":"1991","unstructured":"Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14:540\u2013545. https:\/\/doi.org\/10.1093\/sleep\/14.6.540","journal-title":"Sleep"},{"key":"2538_CR23","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s00115-017-0333-z","volume":"89","author":"WH Jost","year":"2018","unstructured":"Jost WH, Rizos A, Odin P et al (2018) King\u2019s Parkinson\u2019s Disease Pain Scale. Nervenarzt 89:178\u2013183","journal-title":"Nervenarzt"},{"key":"2538_CR24","doi-asserted-by":"publisher","first-page":"5398","DOI":"10.1007\/s12325-021-01873-w","volume":"38","author":"CM Labandeira","year":"2021","unstructured":"Labandeira CM, Alonso Losada MG, Y\u00e1\u00f1ez Ba\u00f1a R et al (2021) Effectiveness of safinamide over mood in Parkinson\u2019s disease patients: secondary analysis of the open-label study SAFINONMOTOR. Adv Ther 38:5398\u20135411. https:\/\/doi.org\/10.1007\/s12325-021-01873-w","journal-title":"Adv Ther"},{"key":"2538_CR25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.sleep.2017.09.017","volume":"41","author":"C Liguori","year":"2018","unstructured":"Liguori C, Mercuri NB, Stefani A, Pierantozzi M (2018a) Effective treatment of restless legs syndrome by safinamide in Parkinson\u2019s disease patients. Sleep Med 41:113\u2013114. https:\/\/doi.org\/10.1016\/j.sleep.2017.09.017","journal-title":"Sleep Med"},{"key":"2538_CR26","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.parkreldis.2018.06.033","volume":"57","author":"C Liguori","year":"2018","unstructured":"Liguori C, Stefani A, Ruffini R et al (2018b) Safinamide effect on sleep disturbances and daytime sleepiness in motor fluctuating Parkinson\u2019s disease patients: a validated questionnaires-controlled study. Park Relat Disord 57:80\u201381. https:\/\/doi.org\/10.1016\/j.parkreldis.2018.06.033","journal-title":"Park Relat Disord"},{"key":"2538_CR27","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s10072-018-3272-y","volume":"39","author":"F Mancini","year":"2018","unstructured":"Mancini F, Di Fonzo A, Lazzeri G et al (2018) Real life evaluation of safinamide effectiveness in Parkinson\u2019s disease. Neurol Sci 39:733\u2013739. https:\/\/doi.org\/10.1007\/s10072-018-3272-y","journal-title":"Neurol Sci"},{"key":"2538_CR28","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/mds.23462","volume":"26","author":"P Martinez-Martin","year":"2011","unstructured":"Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR (2011) The impact of non-motor symptoms on health-related quality of life of patients with Parkinson\u2019s disease. Mov Disord 26:399\u2013406. https:\/\/doi.org\/10.1002\/mds.23462","journal-title":"Mov Disord"},{"key":"2538_CR29","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3389\/fphar.2020.593822","volume":"11","author":"C Miguelez","year":"2020","unstructured":"Miguelez C, De Deurwaerd\u00e8re P, Sgambato V (2020) Editorial: non-dopaminergic systems in Parkinson\u2019s Disease. Front Pharmacol 11:10\u201311. https:\/\/doi.org\/10.3389\/fphar.2020.593822","journal-title":"Front Pharmacol"},{"key":"2538_CR30","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1124\/jpet.117.245100","volume":"364","author":"M Morari","year":"2018","unstructured":"Morari M, Brugnoli A, Pisan\u00f2 CA et al (2018) Safinamide differentially modulates in vivo glutamate and GABA release in the rat hippocampus and basal ganglia. J Pharmacol Exp Ther 364:198\u2013206. https:\/\/doi.org\/10.1124\/jpet.117.245100","journal-title":"J Pharmacol Exp Ther"},{"key":"2538_CR31","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1001\/archneur.59.6.986","volume":"59","author":"PE O\u2019Suilleabhain","year":"2002","unstructured":"O\u2019Suilleabhain PE, Dewey RB (2002) Contributions of dopaminergic drugs and disease severity to daytime sleepiness in Parkinson disease. Arch Neurol 59:986\u2013989. https:\/\/doi.org\/10.1001\/archneur.59.6.986","journal-title":"Arch Neurol"},{"key":"2538_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/brainsci11020232","volume":"11","author":"E Pe\u00f1a","year":"2021","unstructured":"Pe\u00f1a E, Borru\u00e9 C, Mata M et al (2021) Impact of SAfinamide on depressive symptoms in parkinson\u2019s disease patients (SADness-PD Study): a multicenter retrospective study. Brain Sci 11:1\u201311. https:\/\/doi.org\/10.3390\/brainsci11020232","journal-title":"Brain Sci"},{"key":"2538_CR33","doi-asserted-by":"publisher","first-page":"108006","DOI":"10.1016\/j.neuropharm.2020.108006","volume":"167","author":"CA Pisan\u00f2","year":"2020","unstructured":"Pisan\u00f2 CA, Brugnoli A, Novello S et al (2020) Safinamide inhibits in vivo glutamate release in a rat model of Parkinson\u2019s disease. Neuropharmacology 167:108006. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108006","journal-title":"Neuropharmacology"},{"key":"2538_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM et al (2017) Parkinson disease. Nat Rev Dis Prim 3:1\u201321. https:\/\/doi.org\/10.1038\/nrdp.2017.13","journal-title":"Nat Rev Dis Prim"},{"key":"2538_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-021-05607-2","author":"D Santos Garc\u00eda","year":"2021","unstructured":"Santos Garc\u00eda D, Cabo L\u00f3pez I, Labandeira Guerra C et al (2021) Safinamide improves sleep and daytime sleepiness in Parkinson\u2019s disease: results from the SAFINONMOTOR study. Neurol Sci. https:\/\/doi.org\/10.1007\/s10072-021-05607-2","journal-title":"Neurol Sci"},{"key":"2538_CR36","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nrn.2017.62","volume":"18","author":"AHV Schapira","year":"2017","unstructured":"Schapira AHV, Chaudhuri KR, Jenner P (2017) Non-motor features of Parkinson disease. Nat Rev Neurosci 18:435\u2013450. https:\/\/doi.org\/10.1038\/nrn.2017.62","journal-title":"Nat Rev Neurosci"},{"key":"2538_CR37","unstructured":"Sica C, Ghisi M (2007) The Italian versions of the Beck Anxiety Inventory and the Beck Depression Inventory-II: Psychometric properties and discriminant power. In: Leading-edge psychological tests and testing research. Nova Science Publishers, Sica, Claudio: Dipartimento di Psicologia, University of Firenze Via San Niccolo, Firenze, Italy, 93, 50125, claudio.sica@unifi.it, pp 27\u201350"},{"key":"2538_CR38","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.parkreldis.2019.05.028","volume":"65","author":"M Siciliano","year":"2019","unstructured":"Siciliano M, Chiorri C, De Micco R et al (2019) Fatigue in Parkinson\u2019s disease: Italian validation of the Parkinson Fatigue Scale and the Fatigue Severity Scale using a Rasch analysis approach. Park Relat Disord 65:105\u2013110. https:\/\/doi.org\/10.1016\/j.parkreldis.2019.05.028","journal-title":"Park Relat Disord"},{"key":"2538_CR39","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1111\/j.1468-1331.2010.03063.x","volume":"17","author":"PO Valko","year":"2010","unstructured":"Valko PO, Waldvogel D, Weller M et al (2010) Fatigue and excessive daytime sleepiness in idiopathic Parkinson\u2019s disease differently correlate with motor symptoms, depression and dopaminergic treatment. Eur J Neurol 17:1428\u20131436. https:\/\/doi.org\/10.1111\/j.1468-1331.2010.03063.x","journal-title":"Eur J Neurol"},{"key":"2538_CR40","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s100720300004","volume":"23","author":"L Vignatelli","year":"2003","unstructured":"Vignatelli L, Plazzi G, Barbato A et al (2003) Italian version of the Epworth sleepiness scale: external validity. Neurol Sci 23:295\u2013300. https:\/\/doi.org\/10.1007\/s100720300004","journal-title":"Neurol Sci"},{"key":"2538_CR41","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/mdc3.12063","volume":"1","author":"EYH Yeung","year":"2014","unstructured":"Yeung EYH, Cavanna AE (2014) Sleep attacks in patients with Parkinson\u2019s disease on dopaminergic medications: a systematic review. Mov Disord Clin Pract 1:307\u2013316. https:\/\/doi.org\/10.1002\/mdc3.12063","journal-title":"Mov Disord Clin Pract"},{"key":"2538_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/npjparkd.2015.13","author":"P Zis","year":"2015","unstructured":"Zis P, Erro R, Walton CC et al (2015) The range and nature of non-motor symptoms in drug-naive Parkinson\u2019s disease patients: a state-of-the-art systematic review. Park Dis. https:\/\/doi.org\/10.1038\/npjparkd.2015.13","journal-title":"Park Dis"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-022-02538-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-022-02538-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-022-02538-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T15:08:15Z","timestamp":1665414495000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-022-02538-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,7]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["2538"],"URL":"https:\/\/doi.org\/10.1007\/s00702-022-02538-w","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,7]]},"assertion":[{"value":"21 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by an unrestricted grant from Zambon to A.S. No other financial disclosures or conflict of interests related to this study are present.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}